InsidersTradesSigma
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Discover the detailed record of transactions filed by BORMANN-KENNEDY BARBARA-JEAN ANNE, Director. Director active across 1 company, notably Xeris Biopharma Holdings, Inc.. Cumulatively, 5 disclosures have been published. Split: 0 buy · 1 sell. Total volume traded: €84k. Activity tracked since 8 June 2022. The latest transaction was disclosed on 4 June 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
5 of 5 declarations
Barbara-Jean Anne Bormann-Kennedy is a Director at Xeris Biopharma Holdings, Inc. She plays a vital role in corporate governance and strategic decision-making. As a board member, she helps guide Xeris Biopharma's growth initiatives. Her experience in the biopharmaceutical sector is an asset for the company.